title: Treatment of essential thrombocythemia with anagrelide.
abstract: Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET.
authors.affiliation: Department of Pediatrics, Texas Children's Cancer Center, Houston 77030, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Chintagumpala
authors.forename: L L
authors.initials: LL
authors.lastname: Kennedy
authors.forename: C P
authors.initials: CP
authors.lastname: Steuber
mesh_terms: D000293:Adolescent; D001772:Blood Cell Count / Q000187:drug effects; D001856:Bone Marrow Examination; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide